Ascendis Pharma’s Q3 Growth and Strategic Moves
Ascendis Pharma (ASND) has released an update. Ascendis Pharma reported a revenue of €57.8 million in Q3 2024, driven by product launches and ...
GlobalData on MSN14h
Metsera raises $215m in Series B round for weight loss candidates
Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.
Business Insider3d
Ascendis Pharma (ASND) Receives a Hold from Morgan Stanley
Ascendis Pharma (ASND) Company Description: Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a ...
Royalty Pharma: Massive Opportunity Ahead
Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...